Showing 8321-8330 of 8879 results for "".
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Laser Procedures Seem Generally OK for Psoriasis Patients: Analysishttps://practicaldermatology.com/news/laser-procedures-seem-generally-ok-for-psoriasis-patients-analysis/2458515/Patients with psoriasis who undergo laser procedures do not appear to be at risk for koebnerization, according to research published this spring in Dermatologic Surge
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Dr. Ann Marshak-Rothstein Takes Home 2016 Lupus Insight Prize for Cutaneous Lupus Researchhttps://practicaldermatology.com/news/dr-ann-marshak-rothstein-takes-home-2016-lupus-insight-prize-for-cutaneous-lupus-research/2458520/Ann Marshak-Rothstein, PhD, a professor of Medicine/Rheumatology at the University of Massachusetts Medical received the 2016 Lupus Insight Prize for her research on cutaneous lupus. The award was announced at FOCIS 2016, the 16th Annual M
- Sciton Introduces diVa Laser for Vaginal Rejuvenationhttps://practicaldermatology.com/news/sciton-introduced-diva-laser-for-vaginal-rejuvenation/2458524/Sciton introduced diVa, a hybrid fractional laser (HFL) for the treatment of vaginal tissue. Major life events like childbirth and menopause can cause changes in vaginal health. Excessive stretching of the vaginal tissue commonly happens from childbirth. Vaginal tissue may not fully recov
- Preston Romm Joins Suneva Medical As Chief Operating Officerhttps://practicaldermatology.com/news/preston-romm-joins-suneva-medical-as-chief-operating-officer/2458528/Suneva Medical Inc. appointed Preston Romm to chief operating officer (COO). Romm joins Suneva Medical with more than 30 years of experience and will be responsible for leading the company's sales, marketing and operations. Previously serving as president of Oba
- With $25 Million Financing, Suneva Medical Gets Ready to Up Their Gamehttps://practicaldermatology.com/news/with-25-million-financing-suneva-medical-gets-ready-to-up-their-game/2458531/Suneva Medical closed $25 million financing to support continued growth opportunities, the company reports. This financing, which includes $25 million equity investment from Essex Woodlands, strengthens Suneva Medi
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Studyhttps://practicaldermatology.com/news/dupilumab-with-topical-corticosteroids-tcs-superior-to-tcs-alone-in-long-term-atopic-dermatitis-study/2458541/Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD CHRONOS study. Reported by Regeneron Pharmaceuticals, Inc. and Sanofi, the phase 3 study involved